

Technical Information Report

AAMI/ISO TIR37137: 2014

Cardiovascular biological
evaluation of medical
devices — Guidance for
absorbable implants

Cardiovascular biological evaluation of medical devices — Guidance for absorbable implants

Approved 24 September 2014 by
Association for the Advancement of Medical Instrumentation

Registered 28 November 2014 by
American National Standards Institute

Abstract: provide interim part-by-part guidance on potential adjustments to various test methods within the 10993 series to account for the intentional release of soluble components or degradation products from absorbable medical devices.

Keywords: biological evaluation, absorbable implants, cardiovascular

Published by

Association for the Advancement of Medical Instrumentation
4301 N. Fairfax Dr., Ste. 301
Arlington, VA 22203-1633
www.aami.org

© 2014 by the Association for the Advancement of Medical Instrumentation

All Rights Reserved

This publication is subject to copyright claims of ISO, ANSI, and AAMI. No part of this publication may be reproduced or distributed in any form, including an electronic retrieval system, without the prior written permission of AAMI. All requests pertaining to this draft should be submitted to AAMI. It is illegal under federal law (17 U.S.C. § 101, *et seq.*) to make copies of all or any part of this document (whether internally or externally) without the prior written permission of the Association for the Advancement of Medical Instrumentation. Violators risk legal action, including civil and criminal penalties, and damages of \$100,000 per offense. For permission regarding the use of all or any part of this document, contact AAMI, 4301 N. Fairfax Dr., Ste. 301, Arlington, VA 22203-1633. Phone: (703) 525-4890; Fax: (703) 525-1067.

Printed in the United States of America

ISBN 1-57020-575-2

AAMI Technical Information Report

A technical information report (TIR) is a publication of the Association for the Advancement of Medical Instrumentation (AAMI) Standards Board that addresses a particular aspect of medical technology.

Although the material presented in a TIR may need further evaluation by experts, releasing the information is valuable because the industry and the professions have an immediate need for it.

A TIR differs markedly from a standard or recommended practice, and readers should understand the differences between these documents.

Standards and recommended practices are subject to a formal process of committee approval, public review, and resolution of all comments. This process of consensus is supervised by the AAMI Standards Board and, in the case of American National Standards, by the American National Standards Institute.

A TIR is not subject to the same formal approval process as a standard. However, a TIR is approved for distribution by a technical committee and the AAMI Standards Board.

Another difference is that, although both standards and TIRs are periodically reviewed, a standard must be acted on—reaffirmed, revised, or withdrawn—and the action formally approved usually every five years but at least every 10 years. For a TIR, AAMI consults with a technical committee about five years after the publication date (and periodically thereafter) for guidance on whether the document is still useful—that is, to check that the information is relevant or of historical value. If the information is not useful, the TIR is removed from circulation.

A TIR may be developed because it is more responsive to underlying safety or performance issues than a standard or recommended practice, or because achieving consensus is extremely difficult or unlikely. Unlike a standard, a TIR permits the inclusion of differing viewpoints on technical issues.

CAUTION NOTICE: This AAMI TIR may be revised or withdrawn at any time. Because it addresses a rapidly evolving field or technology, readers are cautioned to ensure that they have also considered information that may be more recent than this document.

All standards, recommended practices, technical information reports, and other types of technical documents developed by AAMI are voluntary, and their application is solely within the discretion and professional judgment of the user of the document. Occasionally, voluntary technical documents are adopted by government regulatory agencies or procurement authorities, in which case the adopting agency is responsible for enforcement of its rules and regulations.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Dr., Suite 301, Arlington, VA 22203-1633.

ANSI Registration

Publication of this Technical Report that has been registered with ANSI has been approved by the Accredited Standards Developer (AAMI, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633). This document is registered as a Technical Report according to the Procedures for the Registration of Technical Reports with ANSI. This document is not an American National Standard and the material contained herein is not normative in nature.

Comments on this technical information report are invited and should be sent to AAMI, Attn: Standards Department, 4301 N. Fairfax Drive, Suite 301, Arlington, VA 22203-1633.

Contents

Page

Glossary of equivalent standards	v
Committee representation	vi
Background of AAMI adoption of ISO/TR 37137:2014	vii
1 Scope	1
2 Terms and definitions	1
3 General considerations	1
4 Sterilization considerations	2
5 Drug-device combination product considerations	3
6 Part listing and description of absorbable related issues in addition to the relevant parts of ISO 10993 series "Biological evaluation of medical devices"	3
6.1 ISO 10993-1:2009, Evaluation and testing within a risk management process	3
6.2 ISO 10993-2:2006, Animal welfare requirements	4
6.3 ISO 10993-3:2003, Tests for genotoxicity, carcinogenicity and reproductive toxicity	4
6.4 ISO 10993-4:2002, Selection of tests for interactions with blood	4
6.5 ISO 10993-5:2009, Tests for <i>in vitro</i> cytotoxicity	5
6.6 ISO 10993-6:2007, Tests for local effects after implantation	6
6.7 ISO 10993-7:2008, Ethylene oxide sterilization residuals	7
6.8 ISO 10993-9:2009, Framework for identification and quantification of potential degradation products	8
6.9 ISO 10993-10:2010, Tests for irritation and delayed-type hypersensitivity	8
6.10 ISO 10993-11:2006, Biological evaluation of medical devices — Part 11: Tests for systemic toxicity	8
6.11 ISO 10993-12:2012, Sample preparation and reference materials	9
6.12 ISO 10993-13:2010, Identification and quantification of degradation products from polymeric medical devices	12
6.13 ISO 10993-14:2001, Identification and quantification of degradation products from ceramics	12
6.14 ISO 10993-15:2000, Identification and quantification of degradation products from metals and alloys	12
6.15 ISO 10993-16:2010, Toxicokinetic study design for degradation products and leachables	12
6.16 ISO 10993-17:2002, Establishment of allowable limits for leachable substances	12
6.17 ISO 10993-18:2005, Chemical characterization of materials	12
6.18 ISO/TS 10993-19:2006, Physico-chemical, morphological and topographical characterization of materials	13
6.19 ISO/TS 10993-20:2006, Principles and methods for immunotoxicology testing of medical devices	13
Annex A (informative) Nomenclature of absorb, degrade and related terms	14
Bibliography	15

Glossary of equivalent standards

International Standards adopted in the United States may include normative references to other International Standards. AAMI maintains a current list of each International Standard that has been adopted by AAMI (and ANSI). Available on the AAMI website at the address below, this list gives the corresponding U.S. designation and level of equivalency to the International Standard.

www.aami.org/standards/glossary.pdf

Committee representation

Association for the Advancement of Medical Instrumentation

Biological Evaluation Committee

The adoption of ISO/TR 37137:2014 as an AAMI Technical Information Report was initiated by the AAMI Biological Evaluation Committee, which also functions as a U.S. Technical Advisory Group to the relevant work in the International Organization for Standardization (ISO) and the AAMI Strategic Approach to Biological Assessment Working Group.

At the time this document was published, the **AAMI Biological Evaluation Committee** had the following members:

<i>Co-chairs</i>	Ronald P. Brown, FDA/CDRH Jon Cammack, PhD DABT, Medimmune LLC
<i>Members</i>	James M. Anderson, MD PhD, Case Western Reserve Univ Joseph Carraway, DVM, NAMSA Philippe Hasgall, Zimmer Inc Richard W. Hutchinson, DVM PhD DABT, Johnson & Johnson Laurence Lister, BS, Toxikon Corporation David Maillett, Edwards LifeSciences Anita Y. Sawyer, Becton Dickinson & Company Brian Wallace, Intuitive Surgical Inc Michael F. Wolf, Medtronic Inc WHQ Campus
<i>Alternates</i>	Kelly P. Coleman, PhD DABT, Medtronic Inc WHQ Campus John Iannone, BME, Toxikon Corporation Hooman Kashani, Intuitive Surgical Inc Yijun Lu, PhD, Johnson & Johnson Larry J. Thompson, Zimmer Inc

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies

At the time this document was published, the **AAMI Strategic Approach to Biological Assessment Working Group** had the following members:

<i>Chair</i>	Jon Cammack, PhD DABT, Medimmune LLC
<i>Members</i>	Carolyn Braithwaite-Nelson, Spectranetics Corporation David J. Brodersen, Covidien Ronald P. Brown, FDA/CDRH Jon Cammack, PhD DABT, Medimmune LLC Kelly P. Coleman, PhD DABT, Medtronic Inc WHQ Campus John Dooley, PhD DABT, Johnson & Johnson Gloria H. Frost, PhD DABT, Cardinal Health (MP&S) Joel R. Gorski, PhD, NAMSA Niranjan Goud, PhD, Boston Scientific Corporation John Iannone, BME, Toxikon Corporation Keith A. Knisley, PhD, WL Gore & Associates Inc Mollie Love, Smiths Medical Richard Lukacovic, Baxter Healthcare Corporation Lori H. Moilanen, PhD DABT, 3M Healthcare Dave Parente, Ecolab Rodney D. Parker, Stryker Instruments Division Deanna Porter, St Jude Medical Inc Karen Sargis, CareFusion Sharmilee Sawant, PhD, Halyard Health Anita Y. Sawyer, Becton Dickinson & Company Brenda Seidman, PhD MS, Seidman Regulatory Toxicology, LLC Nancy J. Stark, PhD, Clinical Device Group Inc April T. Veoukas, JD, Abbott Laboratories Brian Wallace, Intuitive Surgical Inc

Sean Richard Werner, PhD, Cook Inc
Randy D. White, PhD, WuXi AppTec Inc

Alternates

Joseph Carraway, DVM, NAMSA
Shawn Deng, Medtronic Inc WHQ Campus
Chandramallika Ghosh, PhD, FDA/CDRH
Hooman Kashani, Intuitive Surgical Inc
Anita Kore, DVM, PhD, 3M Healthcare
Antonio Lopez-Feliciano, CareFusion
Lisa Olson, WuXi AppTec Inc
Laura Perkins, Abbott Laboratories
Robert T. Przygoda, PhD, Johnson & Johnson
Edward Reverdy, PhD, Boston Scientific Corporation
Karen Ruble, Kimberly-Clark Corporation
Brian Sidow, Stryker Instruments Division
Lindsey K. Spaude, BS, Smiths Medical
Hemant Vekaria, St Jude Medical Inc

NOTE—Participation by federal agency representatives in the development of this standard does not constitute endorsement by the federal government or any of its agencies.
